日本語AIでPubMedを検索
ラットにおけるテリパラチドの投薬関連顎骨壊死に対する予防効果
Preventive effect of teriparatide on medication-related osteonecrosis of the jaw in rats.
PMID: 37726385
抄録
本研究は、ゾレドロン酸を投与した両側卵巣摘出雌性ラットを用いて、歯周病変による抜歯前の薬物関連顎骨壊死(MRONJ)に対するテリパラチド(TPD)投与の予防効果を検討することを目的とした。30匹の骨格成熟Sprague-Dawleyラットを無作為に3群に分けた:コントロール(CONT、n=10)、ゾレドロン酸(ZA、n=10)、ゾレドロン酸とテリパラチド(ZA-TPD、n=10)。ラットは抜歯後8週目に犠牲となった。脛骨のマイクロCT分析では、骨密度はCONT群で最も高く、次いでZA群とZA-TPD群であった(CONT/ZA、p=0.009;CONT/ZA-TPD、p<0.001;ZA/ZA-TPD、p<0.001)。抜歯部位の海綿骨分析では、比骨表面(CONT/ZA、p=0.010;CONT/ZA-TPD、p=0.007;ZA/ZA-TPD、p=0.002)および海綿骨の厚さ(CONT/ZA-TPD、p=0.002;ZA/ZA-TPD、p=0.002)に有意差が認められた。抜歯部位の組織学的解析では、ZA群で特徴的なMRONJ病変が認められた。骨壊死,炎症細胞,seakestrumはZA-TPD群ではZA群よりも少ない頻度で観察された.結論として、抜歯前のTPD投与は、ゾレドロン酸投与ラットにおけるMRONJの発生を抑制し、その予防効果を確認した。
This study aimed to investigate the preventive effect of teriparatide (TPD) administration on medication-related osteonecrosis of the jaw (MRONJ) before tooth extraction due to periodontal lesions in bilaterally ovariectomized female rats treated with zoledronic acid. Thirty skeletally mature Sprague-Dawley rats were randomly divided into three groups: control (CONT, n = 10), zoledronic acid (ZA, n = 10), and zoledronic acid and teriparatide (ZA-TPD, n = 10). The rats were sacrificed 8 weeks after tooth extraction. Micro-computed tomography analysis of the tibia showed that bone mineral density was highest in the CONT, followed by that in the ZA and ZA-TPD groups (CONT/ZA, p = 0.009; CONT/ZA-TPD, p < 0.001; ZA/ZA-TPD, p < 0.001). In the trabecular bone analysis of the extraction site, significant differences in specific bone surface (CONT/ZA, p = 0.010; CONT/ZA-TPD, p = 0.007; ZA/ZA-TPD, p = 0.002) and trabecular thickness (CONT/ZA-TPD, p = 0.002; ZA/ZA-TPD, p = 0.002) were observed. Histological analyses of the extraction sites revealed characteristic MRONJ lesions in the ZA group. Osteonecrosis, inflammatory cells, and sequestrum were less frequently observed in the ZA-TPD group than in the ZA group. In conclusion, TPD administration before tooth extraction helped reduce the occurrence of MRONJ in rats treated with zoledronic acid, confirming its preventative effects.